Articles Tagged With:
-
Q&A Part 3: IRBs Learn Positive and Instructional Lessons from Pandemic
IRB experts share the ways in which the pandemic has spurred innovation in their institutions.
-
Q&A Part 2: How IRB Leaders Helped Staff, Board Members Cope with Uncertainty
Communication, stress, and anxiety were top concerns for IRB leaders and staff during the early days of the COVID-19 pandemic.
-
Q&A Part 1: IRBs Face Their Toughest Challenges with COVID-19
IRB leaders describe the challenges staff faced during the transition to remote working.
-
IRB Pandemic Impact Report
In this question and answer special report, a dozen IRB administrators, directors, chairs, and other leaders from across the United States were asked about their facilities’ experiences during the COVID-19 pandemic’s early weeks.
-
IRB Experts Offer Advice for Changing Research Landscape
It is clear that clinical trials now exist in a different world from what researchers, IRBs, and sponsors experienced in 2019. The key challenges are how to restart clinical trials, how to return to in-person visits, and how to manage the growing number of studies related to COVID-19.
-
Intermittent Fasting: A Faster Way to a Longer Life?
Intermittent fasting, which once was strictly in the purview of religion and health fads, has undergone a rapid increase in scientific interest. Studies now demonstrate the positive impact that various methods of intermittent fasting can have on overall health.
-
ACS Prepares Surgeons for Resuming Elective Procedures
The COVID-19 pandemic forced many facilities to press pause on regular operations. Now, some are ready to chart a course back toward some sense of normalcy.
-
Infectious Disease Alert Updates
Complications of Typhoid Fever; Do I Smell a Rat? Or Is the Rat Smelling Me? Cloth Masks — Just for Looks?
-
Lefamulin: Formulary Considerations
The Food and Drug Administration (FDA) recently approved lefamulin for the treatment of adults with community-acquired bacterial pneumonia (CABP).
-
Antibiotic Therapy to Reduce the Incidence of Ventilator-Associated Pneumonia After Cardiac Arrest
In this prospective, randomized trial, intravenous amoxicillin-clavulanate (dosed three times daily and given for two days) administered to patients admitted with out-of-hospital cardiac arrest due to a shockable rhythm reduced the incidence of early ventilator-associated pneumonia.